Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Type 1 Diabetes (T1D) Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Type 1 Diabetes (T1D) Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Rapid Acting Insulin Analogs
      • 1.3.3 Long Acting Insulin Analogs
      • 1.3.4 Premix Insulin Analogs
    • 1.4 Market Segment by Application
      • 1.4.1 Global Type 1 Diabetes (T1D) Market Share by Application (2019-2025)
      • 1.4.2 Children
      • 1.4.3 Adults
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Type 1 Diabetes (T1D) Market Size
      • 2.1.1 Global Type 1 Diabetes (T1D) Revenue 2014-2025
      • 2.1.2 Global Type 1 Diabetes (T1D) Sales 2014-2025
    • 2.2 Type 1 Diabetes (T1D) Growth Rate by Regions
      • 2.2.1 Global Type 1 Diabetes (T1D) Sales by Regions 2014-2019
      • 2.2.2 Global Type 1 Diabetes (T1D) Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Type 1 Diabetes (T1D) Sales by Manufacturers
      • 3.1.1 Type 1 Diabetes (T1D) Sales by Manufacturers 2014-2019
      • 3.1.2 Type 1 Diabetes (T1D) Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Type 1 Diabetes (T1D) Revenue by Manufacturers (2014-2019)
      • 3.2.2 Type 1 Diabetes (T1D) Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Type 1 Diabetes (T1D) Market Concentration Ratio (CR5 and HHI)
    • 3.3 Type 1 Diabetes (T1D) Price by Manufacturers
    • 3.4 Key Manufacturers Type 1 Diabetes (T1D) Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Type 1 Diabetes (T1D) Market
    • 3.6 Key Manufacturers Type 1 Diabetes (T1D) Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Rapid Acting Insulin Analogs Sales and Revenue (2014-2019)
      • 4.1.2 Long Acting Insulin Analogs Sales and Revenue (2014-2019)
      • 4.1.3 Premix Insulin Analogs Sales and Revenue (2014-2019)
    • 4.2 Global Type 1 Diabetes (T1D) Sales Market Share by Type
    • 4.3 Global Type 1 Diabetes (T1D) Revenue Market Share by Type
    • 4.4 Type 1 Diabetes (T1D) Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Type 1 Diabetes (T1D) Sales by Application

    6 United States

    • 6.1 United States Type 1 Diabetes (T1D) Breakdown Data by Company
    • 6.2 United States Type 1 Diabetes (T1D) Breakdown Data by Type
    • 6.3 United States Type 1 Diabetes (T1D) Breakdown Data by Application

    7 European Union

    • 7.1 European Union Type 1 Diabetes (T1D) Breakdown Data by Company
    • 7.2 European Union Type 1 Diabetes (T1D) Breakdown Data by Type
    • 7.3 European Union Type 1 Diabetes (T1D) Breakdown Data by Application

    8 China

    • 8.1 China Type 1 Diabetes (T1D) Breakdown Data by Company
    • 8.2 China Type 1 Diabetes (T1D) Breakdown Data by Type
    • 8.3 China Type 1 Diabetes (T1D) Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Type 1 Diabetes (T1D) Breakdown Data by Company
    • 9.2 Rest of World Type 1 Diabetes (T1D) Breakdown Data by Type
    • 9.3 Rest of World Type 1 Diabetes (T1D) Breakdown Data by Application
    • 9.4 Rest of World Type 1 Diabetes (T1D) Breakdown Data by Countries
      • 9.4.1 Rest of World Type 1 Diabetes (T1D) Sales by Countries
      • 9.4.2 Rest of World Type 1 Diabetes (T1D) Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Novo Nordisk
      • 10.1.1 Novo Nordisk Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.1.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.1.5 Novo Nordisk Recent Development
    • 10.2 Sanofi
      • 10.2.1 Sanofi Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.2.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.2.5 Sanofi Recent Development
    • 10.3 Eli Lilly
      • 10.3.1 Eli Lilly Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.3.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.3.5 Eli Lilly Recent Development
    • 10.4 Merck
      • 10.4.1 Merck Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.4.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.4.5 Merck Recent Development
    • 10.5 Boehringer Ingelheim
      • 10.5.1 Boehringer Ingelheim Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.5.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.5.5 Boehringer Ingelheim Recent Development
    • 10.6 Samsung Bioepis
      • 10.6.1 Samsung Bioepis Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.6.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.6.5 Samsung Bioepis Recent Development
    • 10.7 Biocon
      • 10.7.1 Biocon Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.7.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.7.5 Biocon Recent Development
    • 10.8 Astellas
      • 10.8.1 Astellas Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.8.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.8.5 Astellas Recent Development
    • 10.9 Janssen
      • 10.9.1 Janssen Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.9.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.9.5 Janssen Recent Development
    • 10.10 Bristol-Myers Squibb
      • 10.10.1 Bristol-Myers Squibb Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Type 1 Diabetes (T1D)
      • 10.10.4 Type 1 Diabetes (T1D) Product Introduction
      • 10.10.5 Bristol-Myers Squibb Recent Development
    • 10.11 Lexicon
    • 10.12 Sanofi

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Type 1 Diabetes (T1D) Sales Channels
      • 11.2.2 Type 1 Diabetes (T1D) Distributors
    • 11.3 Type 1 Diabetes (T1D) Customers

    12 Market Forecast

    • 12.1 Global Type 1 Diabetes (T1D) Sales and Revenue Forecast 2019-2025
    • 12.2 Global Type 1 Diabetes (T1D) Sales Forecast by Type
    • 12.3 Global Type 1 Diabetes (T1D) Sales Forecast by Application
    • 12.4 Type 1 Diabetes (T1D) Forecast by Regions
      • 12.4.1 Global Type 1 Diabetes (T1D) Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Type 1 Diabetes (T1D) Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body’s immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.
      Sedentary lifestyle, unhealthy diet, lack of exercise and increasing prevalence of diabetes are key driver for Type 1 Diabetes (T1D) market. Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. While insulin therapy keeps people with T1D alive and can help keep blood-glucose levels within recommended range, it is not a cure, nor does it prevent the possibility of T1D’s serious effects. Although T1D is a serious and challenging disease, long-term management options continue to evolve, allowing those with T1D to have full and active lives. Asia Pacific region recorded the highest growth rate over the forecast period owing to the increasingly sedentary lifestyles, obese population, and improper food habits. North America accounted for more than 50% of the total market share over the forecast period.
      In 2019, the market size of Type 1 Diabetes (T1D) is 1960 million US$ and it will reach 2810 million US$ in 2025, growing at a CAGR of 4.6% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Type 1 Diabetes (T1D).

      This report studies the global market size of Type 1 Diabetes (T1D), especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Type 1 Diabetes (T1D) sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Novo Nordisk
      Sanofi
      Eli Lilly
      Merck
      Boehringer Ingelheim
      Samsung Bioepis
      Biocon
      Astellas
      Janssen
      Bristol-Myers Squibb
      Lexicon
      Sanofi

      Market Segment by Product Type
      Rapid Acting Insulin Analogs
      Long Acting Insulin Analogs
      Premix Insulin Analogs

      Market Segment by Application
      Children
      Adults

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Type 1 Diabetes (T1D) status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Type 1 Diabetes (T1D) manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Type 1 Diabetes (T1D) are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now